Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Metabolic screening in children receiving antipsychotic drug treatment.

Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, Campagna E, Newcomer JW.

Arch Pediatr Adolesc Med. 2010 Apr;164(4):344-51. doi: 10.1001/archpediatrics.2010.48. Erratum in: Arch Pediatr Adolesc Med. 2010 Jun;164(6):584.

PMID:
20368487
[PubMed - indexed for MEDLINE]
2.

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW.

Arch Gen Psychiatry. 2010 Jan;67(1):17-24. doi: 10.1001/archgenpsychiatry.2009.179.

PMID:
20048219
[PubMed - indexed for MEDLINE]
3.

Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data.

Morrato EH, Newcomer JW, Allen RR, Valuck RJ.

J Clin Psychiatry. 2008 Feb;69(2):316-22.

PMID:
18251625
[PubMed - indexed for MEDLINE]
4.

Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics.

Barnett M, VonMuenster S, Wehring H, Popish S, McDonald K, Walker VM, Perry P.

Ann Clin Psychiatry. 2010 Feb;22(1):9-18.

PMID:
20196978
[PubMed - indexed for MEDLINE]
5.

Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.

Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J.

J Clin Psychopharmacol. 2009 Feb;29(1):26-32. doi: 10.1097/JCP.0b013e31819294cb.

PMID:
19142103
[PubMed - indexed for MEDLINE]
6.

Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.

Moeller KE, Rigler SK, Mayorga A, Nazir N, Shireman TI.

Schizophr Res. 2011 Mar;126(1-3):117-23. doi: 10.1016/j.schres.2010.11.015. Epub 2010 Dec 18.

PMID:
21168994
[PubMed - indexed for MEDLINE]
7.

Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population.

Hsu C, Ried LD, Bengtson MA, Garman PM, McConkey JR, Rahnavard F.

J Am Pharm Assoc (2003). 2008 May-Jun;48(3):393-400. doi: 10.1331/JAPhA.2008.07007.

PMID:
18595825
[PubMed - indexed for MEDLINE]
8.

[Metabolic testing rates after initiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers].

Verdoux H, Gaudron Y, Auleley GR, Deligne J, Blum-Boisgard C, Thiébaut A, Tournier M.

Encephale. 2013 May;39 Suppl 1:S22-8. doi: 10.1016/j.encep.2012.10.009. Epub 2012 Dec 13. French.

PMID:
23246328
[PubMed - indexed for MEDLINE]
9.

Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.

Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ.

Clin Ther. 2007 Jan;29(1):183-95.

PMID:
17379060
[PubMed - indexed for MEDLINE]
10.

Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study.

Guo JJ, Keck PE Jr, Corey-Lisle PK, Li H, Jiang D, Jang R, L'Italien GJ.

J Clin Psychiatry. 2006 Jul;67(7):1055-61.

PMID:
16889448
[PubMed - indexed for MEDLINE]
11.

Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.

Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B.

Diabetes Care. 2009 Jun;32(6):1037-42. doi: 10.2337/dc08-1720. Epub 2009 Feb 24.

PMID:
19244091
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Prevalence of diabetes mellitus in patients receiving depot neuroleptics or clozapine.

Miller MJ, Molla PM.

Arch Psychiatr Nurs. 2005 Feb;19(1):30-4.

PMID:
15765369
[PubMed - indexed for MEDLINE]
13.

[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].

Rubio G, Gómez-de-la-Cámara A, Ledesma F, Burón JA, Rodríguez-Morales A, Martínez-Junquera G; Grupo Español para el Estudio de la Diabetes en Pacientes Esquizofrénicos.

Med Clin (Barc). 2006 Apr 1;126(12):441-4. Spanish.

PMID:
16620729
[PubMed - indexed for MEDLINE]
14.

LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.

Nag SS, Daniel GW, Bullano MF, Kamal-Bahl S, Sajjan SG, Hu H, Alexander C.

J Manag Care Pharm. 2007 Oct;13(8):652-63.

PMID:
17970603
[PubMed - indexed for MEDLINE]
Free Article
15.

Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.

Østbye T, Curtis LH, Masselink LE, Hutchison S, Wright A, Dans PE, Schulman KA, Krishnan RR.

Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):407-15.

PMID:
15372671
[PubMed - indexed for MEDLINE]
16.

Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications.

Panagiotopoulos C, Ronsley R, Davidson J.

Can J Psychiatry. 2009 Nov;54(11):743-9.

PMID:
19961662
[PubMed - indexed for MEDLINE]
17.

Hyperlipidemia following treatment with antipsychotic medications.

Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ.

Am J Psychiatry. 2006 Oct;163(10):1821-5.

PMID:
17012695
[PubMed - indexed for MEDLINE]
18.

Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.

McIntyre RS, Jerrell JM.

Arch Pediatr Adolesc Med. 2008 Oct;162(10):929-35. doi: 10.1001/archpedi.162.10.929.

PMID:
18838645
[PubMed - indexed for MEDLINE]
19.

Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users.

Morrato EH, Druss BG, Hartung DM, Valuck RJ, Thomas D, Allen R, Campagna E, Newcomer JW.

Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):66-75. doi: 10.1002/pds.2062. Epub 2010 Nov 15.

PMID:
21182154
[PubMed - indexed for MEDLINE]
20.

Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.

Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W.

Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):417-25.

PMID:
15786516
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk